ArticleScientific reports2026
AKAP12-LMOD1 signaling defines stromal CAF activation and epithelial junction loss in colorectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) shows strong heterogeneity in tumor microenvironment (TME) dynamics, but the mechanisms that shape epithelial-stromal crosstalk are still unclear. Here we focus on A-kinase anchor protein 12 (AKAP12) and Leiomodin 1 (LMOD1) and test a compartment-dependent model in which this program aligns with tight-junction features in epithelium but with a fibrotic, immune-suppressive program in stroma. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) were employed to profile gene expression patterns in CRC tissues. Immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) validated protein expression and localization. Cell-cell communication analysis and trajectory inference were used to dissect spatial interaction networks. Functional experiments were employed to validate the role of the AKAP12-LMOD1 axis in CAFs in regulating ECM remodeling and antitumor immunity. AKAP12-LMOD1 exhibited a compartment-dependent pattern in CRC. In ACTA2⁻ epithelial regions, the epithelial AKAP12-LMOD1 signal was lower in tumors than in matched normal epithelium and showed a positive association with the tight-junction marker CLDN1. In ACTA2⁺ stromal regions, AKAP12-LMOD1 was enriched, positively associated with the gap-junction marker GJA4, and higher in tumor stroma than matched normal stroma. In a CAF-macrophage non-contact co-culture model, AKAP12 overexpression supported CAF activation and collagen deposition, and shifted macrophages toward an M2-like phenotype; LMOD1 knockdown or SB-431542 partially reversed these effects. Stromal AKAP12-LMOD1-enriched regions also aligned with fibrosis- and M2-related features, and these stromal patterns were prominent in mucinous carcinoma. This study defines AKAP12-LMOD1 as a compartment-dependent stromal program in CRC that links ACTA2⁺ stroma to gap-junction features, fibrosis, and M2-like macrophage polarization, while showing a distinct epithelial association with tight-junction features. These findings support a stroma-centered working model for AKAP12-LMOD1 in CRC microenvironmental heterogeneity and suggest that stromal modulation of this program, together with targeting fibrosis and M2-like immune features, may be explored as hypothesis-level, subtype-oriented therapeutic directions in stroma-rich CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.